Nanocopoeia Drug Patent Portfolio
Nanocopoeia owns 1 orange book drug protected by 3 US patents Given below is the list of Nanocopoeia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11202778 | Amorphous solid dispersions of dasatinib and uses thereof | 22 Jan, 2041 | Active |
| US11298356 | Amorphous solid dispersions of dasatinib and uses thereof | 22 Jan, 2041 | Active |
| US11324745 | Amorphous solid dispersions of dasatinib and uses thereof | 22 Jan, 2041 | Active |
Latest Legal Activities on Nanocopoeia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nanocopoeia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Recordation of Patent Grant Mailed
Critical
| 10 May, 2022 | US11324745 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 May, 2022 | US11324745 |
|
Email Notification
Critical
| 21 Apr, 2022 | US11324745 |
|
Issue Notification Mailed
Critical
| 20 Apr, 2022 | US11324745 |
| Dispatch to FDC | 12 Apr, 2022 | US11324745 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Apr, 2022 | US11298356 |
|
Application Is Considered Ready for Issue
Critical
| 12 Apr, 2022 | US11324745 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Apr, 2022 | US11298356 |
| Printer Rush- No mailing | 06 Apr, 2022 | US11324745 |
|
Pubs Case Remand to TC
Critical
| 01 Apr, 2022 | US11324745 |
|
Email Notification
Critical
| 01 Apr, 2022 | US11324745 |
|
Email Notification
Critical
| 01 Apr, 2022 | US11298356 |
|
PG-Pub Issue Notification
Critical
| 31 Mar, 2022 | US11324745 |
|
PG-Pub Issue Notification
Critical
| 31 Mar, 2022 | US11298356 |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Mar, 2022 | US11298356 |
Nanocopoeia's Family Patents
Nanocopoeia Drug List
Given below is the complete list of Nanocopoeia's drugs and the patents protecting them.
1. Phyrago
Phyrago is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11202778 | Amorphous solid dispersions of dasatinib and uses thereof |
22 Jan, 2041
(16 years from now)
| Active |
| US11298356 | Amorphous solid dispersions of dasatinib and uses thereof |
22 Jan, 2041
(16 years from now)
| Active |
| US11324745 | Amorphous solid dispersions of dasatinib and uses thereof |
22 Jan, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Phyrago's drug page